Safety Assessment of Ovarian Cryopreservation and Transplantation in Nude Mice Bearing Human Epithelial Ovarian Cancer

  • Zhu, Gen-Hai (Department of Gynecology, Hainan Provincial People's Hospital) ;
  • Wang, Sheng-Tan (Department of Gynecology, Hainan Provincial People's Hospital) ;
  • Yang, Zhao-Xin (Drug Safety Evaluation Center, Hainan Medical College) ;
  • Cai, Jun-Hong (Research Center, Hainan Provincial People's Hospital) ;
  • Chen, Chun-Ying (Department of Gynecology, Hainan Provincial People's Hospital) ;
  • Yao, Mao-Zhong (Drug Safety Evaluation Center, Hainan Medical College) ;
  • Hong, Lan (Department of Gynecology, Hainan Provincial People's Hospital) ;
  • He, Guo-Li (Department of Gynecology, Hainan Provincial People's Hospital) ;
  • Yang, Shu-Ying (Department of Gynecology, Hainan Provincial People's Hospital)
  • Published : 2012.09.30


Objective: Nude mice with orthotopic transplantation of human ovarian epithelial cancer were used to investigate screening criteria for paraneoplastic normal ovarian tissue and the security of the freezing and thawing for ovarian tissue transplantation. Methods: Expression of CK-7, CA125, P53, survivin, MMP-2/TIMP-2 in paraneoplastic normal ovarian tissues were detected by RT-PCR as well as immunohistochemistry. The tissues of the groups with all negative indicators of RT-PCR, all negative indicators of immunohistochemistry, negative expression of CK-7, CA125 and survivin, positive expression of CK-7, CA125 and survivin, cancer tissues and normal ovarian tissues of nude mice were used for freezing and thawing transplantation, to analyze overt and occult carcinogenesis rates after transplantation. Results: When all indicators or the main indicators, CK-7, CA125 and survivin, were negative, tumorigenesis did not occur after transplantation. In addition the occult carcinogenesis rate was lower than in the group with positive expression of CK-7, CA125 and survivin (P<0.01). After subcutaneous and orthotopic transplantation of ovarian tissues, rates did not change (P>0.05). There was no statistical significance among rates after transplantation of ovarian tissues which were obtained under different severity conditions (P>0.05). Conclusion: Negative expression of CK-7, CA125 and survivin can be treated as screening criteria for security of ovarian tissues for transplantation. Immunohistochemical methods can be used as the primary detection approach. Both subcutaneous and orthotopic transplantation are safe. The initial severity does not affect the carcinogenesis rate after tissue transplantation. Freezing and thawing ovarian tissue transplantation in nude mice with human epithelial ovarian carcinoma is feasible and safe.


Supported by : National Natural Science Foundation


  1. Al-Sayed MM, El-Sayed AA, El-Barbary TM, et al (2011). Conservative surgery in patients with malignant ovarian germ cell tumours. J Egypt Soc Parasitol, 41, 737-44
  2. Brun JL, Cortez A, Commo F, et al (2008).Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol, 33, 1239-46.
  3. Dolmans MM, Marinescu C, Saussoy P, et al (2010). Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood, 116, 2908-14.
  4. Donnez J, Dolmans MM (2011). Preservation of fertility in females with haematological malignancy. Br J Haematol, 154, 175-84.
  5. Donnez J, Squifflet J, Jadoul P, et al (2011). Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation. Fertil Steril, 95, 1787.e1-4.
  6. Dykgraaf RH, de Jong D, van Veen M, et al (2009). Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease. Int J Gynecol Cancer, 19, 348-53.
  7. Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, et al (2011). The Polish Ovarian Cancer Study Group (POCSG). Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res, 4, 20.
  8. Finch A, Narod SA(2011). Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: review. Maturitas, 70, 261-5.
  9. Georgescu ES, Goldberg JM, du Plessis SS, et al (2008). Present and future fertility preservation strategies for female cancer patients. Obstet Gynecol Surv, 63, 725-32.
  10. Heatley MK (2008). Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical metaanalysis. Histopathology, 52, 267-76.
  11. Lotz L, Montag M, van der Ven H, et al (2011). Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice--no evidence of malignant cell contamination. Fertil Steril, 95, 2612-4.
  12. MacLennan AH (2011). HRT in difficult circumstances: are there any absolute contraindications? Climacteric, 14, 409-17.
  13. Meirow D, Hardan I, Dor J, et al (2008). Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod, 23, 1007-13.
  14. Michelsen TM, Pripp AH, Tonstad S, et al (2009). Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer, 45, 82-9.
  15. Miller DM, Ehlen TG, Saleh EA (1997). Successful term pregnancy following conservative debulking surgery for a stage IIIA serous low-malignant-potential tumor of the ovary: a case report. Gynecol Oncol, 66, 535-8.
  16. Miller K, Price JH, Dobbs SP, et al (2008). An immunohistochemical and morphological analysis of postchemotherapy ovarian carcinoma. J Clin Pathol, 61, 652-7.
  17. Radford JA, Lieberman BA, Brison DR, et al (2001). Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet, 357, 1172-5.
  18. Rahma OE, Ashtar E, Czystowska M, et al (2012). A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother, 61, 373- 84.
  19. Stranahan D, Cherpelis BS, Glass LF, et al (2009). Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg, 35, 1023-34.
  20. Takami H, Sentani K, Matsuda M, et al (2012). Cytokeratin expression profiling in gastric carcinoma: clinicopathologic significance and comparison with tumor-associated molecules. Pathobiology, 79,154-61.